Tolerability is an essential part of drug therapy and can affect health and economic outcomes. Withdrawal due to adverse reactions of medicines or lack of effectiveness is a major concern in long-term treatments that influences cost-effectiveness analysis. In case of possibility of stopping and switch to other interventions in decision analysis model, overhead costing may affect results and decision-making processes. Thus, modifying of classic decision analysis model seems to be necessary in such cases. My hypothesis is that by the use of a new decision model that can make links between different Markov-like models accurate cost calculation could be achieved. The appearance of model is going to be like a semicycle net. Considering the probability of switching from one treatment strategy to another, one could give more precise economic evaluation results. In the first step, this model needs to be tested and compared with the conventional model. In the second step, the impact of these differences has to be examined in the practical field of health, drug policy and supply management. By applying this new decision model in total health budget, threshold and its consequences on national health accounts and share of health in gross domestic product should be tested.
展开▼
